Organization | Center for International Blood and Marrow Transplant Research

Center for International Blood and Marrow Transplant Research Report issue

Government Phase 2 Phase 3

Founded: Milwaukee WI United States (2004)

Organization Overview

First Clinical Trial

2004

NCT00785525

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Center for International Blood and Marrow Transplant Research

Active Ingredients

Drugs in Phase 3 Trials (35)

allogeneic bone marrow (2 trials)

allogeneic cord blood (1 trial)

allogeneic stem cells (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (5 trials)

autologous cd34+ cells (1 trial)

autologous hematopoietic stem cells (3 trials)

autologous mononuclear stem cell (3 trials)

autologous umbilical cord blood (1 trial)

bone marrow derived mononuclear cells (1 trial)

bortezomib (velcade) (3 trials)

busulfan (Myleran) (10 trials)

carmustine (bicnu) (2 trials)

cyclophosphamide (cytoxan) (18 trials)

cyclosporine (sandimmune) (3 trials)

etanercept (enbrel) (2 trials)

fluconazole (diflucan) (1 trial)

fludarabine (fludara) (17 trials)

lenalidomide (revlimid) (4 trials)

lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam) (1 trial)

melphalan (alkeran) (7 trials)

methotrexate (2 trials)

mycophenolate (CellCept) (12 trials)

naltrexone (revia) (4 trials)

prednisolone (hydeltra) (1 trial)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (2 trials)

ruxolitinib (jakafi) (1 trial)

sargramostim (leukine) (5 trials)

sirolimus (rapamune) (7 trials)

stem cells (1 trial)

tacrolimus (prograf) (10 trials)

thalidomide (Thalomid) (1 trial)

tositumomab (Bexxar) (1 trial)

urea (2 trials)

voriconazole (vfend) (1 trial)

Drugs in Phase 2 Trials (18)

allogeneic hematopoietic stem cells (Hemacord) (3 trials)

bone marrow derived mesenchymal stem cells (1 trial)

cd33 car-t cells (1 trial)

cytarabine (cytosar-u) (1 trial)

dendritic cell tumor fusion vaccine (1 trial)

denileukin diftitox (ontak) (1 trial)

etoposide (vepesid) (2 trials)

Filgrastim (neupogen) (3 trials)

haploidentical mononuclear cells (1 trial)

hydroxyurea (hydrea) (1 trial)

ixazomib (ninlaro) (1 trial)

maraviroc (selzentry) (1 trial)

mesna (mesnex) (7 trials)

moxetumomab pasudotox (Lumoxiti) (1 trial)

pentostatin (nipent) (1 trial)

plerixafor (mozobil) (1 trial)

thiotepa (2 trials)

treosulfan (1 trial)

Drugs in Other Trials (1)

whole blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Anemia, Sickle Cell (Phase 2)

Communicable Diseases (Phase 3)

Graft vs Host Disease (Phase 3)

Hodgkin Disease (Phase 2)

Immune System Diseases (Phase 3)

Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Multiple Myeloma (Phase 3)

Mycoses (Phase 3)

Myelodysplastic-Myeloproliferative Diseases (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 3)

Neoplasm, Residual (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Plasmablastic Lymphoma (Phase 3)

Pneumonia (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 44
# of Trial APIs: 54